Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Phase 3 Trial in Japan
jRCT2080223513Phase 3Completed
- Start
- Apr 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3 trial of pembrolizumab. Started Apr 2017; status: completed.
02
Drugs
Beyond the preview
Go deeper on jRCT2080223513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223513.